Many drugs that have been proposed for treatment of COVID‐19 are reported to cause cardiac adverse events, including ventricular arrhythmias. In order to properly weigh risks against potential benefits, particularly when decisions must be made quickly, mathematical modeling of both drug disposition and drug action can be useful for predicting patient response and making informed decisions. Here we explored the potential effects on cardiac electrophysiology of 4 drugs proposed to treat COVID‐19: lopinavir, ritonavir, chloroquine, and azithromycin, as well as combination therapy involving these drugs. Our study combined simulations of pharmacokinetics (PK) with quantitative systems pharmacology (QSP) modeling of ventricular myocytes to predict potential cardiac adverse events caused by these treatments. Simulation results predicted that drug combinations can lead to greater cellular action potential prolongation, analogous to QT prolongation, compared with drugs given in isolation. The combination effect can result from both pharmacokinetic and pharmacodynamic drug interactions. Importantly, simulations of different patient groups predicted that females with pre‐existing heart disease are especially susceptible to drug‐induced arrhythmias, compared with diseased males or healthy individuals of either sex. Statistical analysis of population simulations revealed the molecular factors that certain females with heart failure especially susceptible to arrhythmias. Overall, the results illustrate how PK and QSP modeling may be combined to more precisely predict cardiac risks of COVID‐19 therapies.
Several drugs proposed for the treatment of COVID-19 have reported cases of cardiac adverse events such as ventricular arrhythmias. To properly weigh risks against potential benefits in a timely manner, mathematical modeling of drug disposition and drug action can be useful for predicting patient response.Here we explored the potential effects on cardiac electrophysiology of 4 COVID-19 proposed treatments: lopinavir, ritonavir, chloroquine, and azithromycin, including combination therapy involving these drugs. To address this, we combined simulations of pharmacokinetics (PK) with mechanistic mathematical modeling of human ventricular myocytes to predict adverse events caused by these treatments. We utilized a mechanistic model to construct heterogenous populations of 4 patient groups (healthy male, healthy female, diseased male, and diseased female) each with 1000 members, and studied the varied responses of drugs and combinations on each population. To determine appropriate drug concentrations for recommended COVID-19 regimen, we implemented PK models for each drug and incorporated these values into the mechanistic model. We found that: (1) drug combinations can lead to greater cellular action potential (AP) prolongation, analogous to QT prolongation, compared with drugs given in isolation; (2) simulations of chloroquine with azithromycin caused a significantly greater increase in AP duration (DAPDz190 ms) compared to lopinavir with ritonavir (DAPDz6 ms); (3) drug effects on different patient populations revealed that females with preexisting heart disease are more susceptible to drug-induced arrhythmias as 85 members formed arrhythmias, and less than 20 in each of the other three; and (4) logistic regression analysis performed on the population showed that higher levels of the sodium-calcium exchanger may predispose certain females with heart failure to drug-induced arrhythmias. Overall, these results illustrate how PK and mechanistic modeling can be combined to precisely predict cardiac arrhythmia susceptibility of COVID-19 therapies.
Many drugs that have been proposed for treatment of COVID-19 are reported to cause cardiac adverse events, including ventricular arrhythmias. In order to properly weigh risks against potential benefits, particularly when decisions must be made quickly, mathematical modeling of both drug disposition and drug action can be useful for predicting patient response and making informed decisions. Here we explored the potential effects on cardiac electrophysiology of 4 drugs proposed to treat COVID-19: lopinavir, ritonavir, chloroquine, and azithromycin, as well as combination therapy involving these drugs. Our study combined simulations of pharmacokinetics (PK) with quantitative systems pharmacology (QSP) modeling of ventricular myocytes to predict potential cardiac adverse events caused by these treatments. Simulation results predicted that drug combinations can lead to greater cellular action potential prolongation, analogous to QT prolongation, compared with drugs given in isolation. The combination effect can result from both pharmacokinetic and pharmacodynamic drug interactions. Importantly, simulations of different patient groups predicted that females with pre-existing heart disease are especially susceptible to drug-induced arrhythmias, compared males with disease or healthy individuals of either sex. Overall, the results illustrate how PK and QSP modeling may be combined to more precisely predict cardiac risks of COVID-19 therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.